Examkin

Soru

Zorluk: OrtaInfectious Diseases

A 58-year-old man is evaluated in the intensive care unit for ongoing antibiotic management. He was admitted 10 days ago following a severe traumatic brain injury that required mechanical ventilation. Five days ago, he developed a new fever of 38.9°C (102.0°F), increased purulent endotracheal secretions, and worsening oxygenation. A portable chest radiograph revealed a new right lower lobe infiltrate. He was empirically started on intravenous vancomycin and piperacillin-tazobactam for presumed ventilator-associated pneumonia. Today, the patient's temperature is 37.2°C (99.0°F), and his oxygen requirements have steadily decreased. A bronchoalveolar lavage culture obtained 48 hours ago has finalized, growing >10510^5 CFU/mL of methicillin-susceptible *Staphylococcus aureus* (MSSA). Blood cultures drawn at the time of the fever remain sterile. Which of the following is the most appropriate next step in pharmacotherapy?

  1. A
    Discontinue piperacillin-tazobactam and continue intravenous vancomycin
  2. B
    Discontinue vancomycin and continue intravenous piperacillin-tazobactam
  3. Discontinue vancomycin and piperacillin-tazobactam, and initiate intravenous cefazolinCevap
  4. D
    Continue both intravenous vancomycin and piperacillin-tazobactam
  5. E
    Discontinue current antibiotics and initiate intravenous daptomycin

Cevap

Discontinue vancomycin and piperacillin-tazobactam, and initiate intravenous cefazolin
The correct approach for a patient with ventilator-associated pneumonia caused by methicillin-susceptible Staphylococcus aureus (MSSA) is to de-escalate from broad-spectrum empiric therapy to a targeted, narrow-spectrum beta-lactam agent. Intravenous cefazolin, nafcillin, or oxacillin are the drugs of choice for severe MSSA infections. They provide superior bactericidal activity, faster clinical resolution, and lower mortality compared to vancomycin for MSSA, while minimizing unnecessary broad-spectrum antimicrobial exposure.

Adım Adım Çözüm

1
Evaluate the patient's clinical trajectory and microbiology results.
The patient is improving, and the bronchoalveolar lavage culture has confirmed a single pathogen: methicillin-susceptible Staphylococcus aureus (MSSA).
Identifying the specific organism and its susceptibility profile allows for the transition from empiric to definitive targeted therapy.
2
Determine the optimal definitive antibiotic for MSSA pneumonia.
Anti-staphylococcal beta-lactams (e.g., cefazolin, nafcillin, oxacillin) are the most effective agents for MSSA.
Beta-lactams provide superior bactericidal activity against MSSA compared to vancomycin, leading to improved clearance and better clinical outcomes.
3
Apply antimicrobial stewardship principles to the current regimen.
The empiric regimen of vancomycin and piperacillin-tazobactam must be stopped and replaced with targeted cefazolin therapy.
Vancomycin is inferior for MSSA, and piperacillin-tazobactam is unnecessarily broad-spectrum, increasing the risk for multi-drug resistant superinfections and unnecessary toxicity.

Anahtar Kavram

Antimicrobial de-escalation for methicillin-susceptible Staphylococcus aureus (MSSA) infections
Bu soruyu puanla

Konular

Infectious Diseases

Bu konudan daha fazla soru